Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from Entresto (+31% cc), Cosentyx (+25% cc), Kesimpta (+49% cc), Kisqali (+49% cc), Pluvicto (+42% cc) and Leqvio (+114% cc)Core operating income margin1 38.7%, +330 basis points (cc), mainly driven by higher net sales Operating income grew +55% (cc, +49% USD); net income up +45% (cc, +39% USD)Core EPS1 grew +24% (cc, ...